Emiltatug Ledadotin Elicits Responses in Aggressive Adenoid Cystic Carcinoma
Emiltatug ledadotin (Emi‑Le), a B7‑H4‑directed antibody‑drug conjugate (ADC), showcased antitumor activity with favorable tolerability in patients with clinicopathologically defined aggressive adenoid cystic carcinoma (ACC).
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Correction: Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features
- A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug
- Deciphering the potential pathogeny of rare tracheal adenoid cystic carcinoma by single‑cell RNA‑sequencing
- Adenoid cystic carcinoma (ACC)
- DAY301 | Day One Biopharmaceuticals